| 2.96 0.24 (8.82%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.7 |
1-year : | 4.32 |
| Resists | First : | 3.17 |
Second : | 3.7 |
| Pivot price | 2.88 |
|||
| Supports | First : | 2.81 |
Second : | 2.59 |
| MAs | MA(5) : | 2.78 | MA(20) : | 2.89 |
| MA(100) : | 3.05 |
MA(250) : | 3.34  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 18.9 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 4.14 | Low : | 2.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AVIR ] has closed below upper band by 28.7%. Bollinger Bands are 14.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.01 - 3.03 | 3.03 - 3.05 |
| Low: | 2.74 - 2.76 | 2.76 - 2.78 |
| Close: | 2.93 - 2.97 | 2.97 - 2.99 |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Mon, 12 May 2025
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Wed, 07 May 2025
Atea Pharmaceuticals (AVIR) Reveals Promising Phase 2 Results for Hepatitis C Treatment | AVIR Stock News - GuruFocus
Thu, 01 May 2025
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - Yahoo Finance
Thu, 17 Apr 2025
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 86 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 11.5 (%) |
| Held by Institutions | 72.3 (%) |
| Shares Short | 2,970 (K) |
| Shares Short P.Month | 2,910 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.7 % |
| Return on Equity (ttm) | -33.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.98 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -136 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -1.49 |
| PEG Ratio | 0 |
| Price to Book value | 0.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|